• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

    11/5/24 6:07:26 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARCT alert in real time by email
    SC 13G 1 arct1027246sc13g.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     ________________ 

      

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. n/a)*

     

     

    Arcturus Therapeutics Holdings Inc.
    (Name of Issuer)
     
    Common stock, par value $0.001 per share
    (Title of Class of Securities)
     
    03969T109
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x       Rule 13d-1(b)

     

    ¨       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

     


    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 9 
     

     

    CUSIP No. 03969T109 13G  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sumitomo Mitsui Trust Group, Inc.  (“SMTG”)

      

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
       

    (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    2,315,294

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    2,315,294

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,315,294

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.56%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, FI

             

     Page 2 of 9 
     

     

    CUSIP No. 03969T109 13G  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Nikko Asset Management Co., Ltd. (“NAM”)

        

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
       

    (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    2,315,294

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    2,315,294

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,315,294

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.56%

    12.

    TYPE OF REPORTING PERSON

     

    IA, HC, FI

             

     Page 3 of 9 
     

     

    Item 1(a).Name of Issuer:

     

    Arcturus Therapeutics Holdings Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    10628 Science Center Drive, Suite 250, San Diego, California 92121

     

    Item 2(a).Name of Person Filing:

     

    Sumitomo Mitsui Trust Group, Inc.

     

    Nikko Asset Management Co., Ltd.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    SMTG: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

     

    NAM: Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo 107-6242, Japan

     

    Item 2(c).Citizenship:

     

    SMTG: Japan

     

    NAM: Japan

     

    Item 2(d).Title of Class of Securities:

     

    Common stock, par value $0.001 per share

     

    Item 2(e).CUSIP Number:

     

    03969T109

     

     Page 4 of 9 
     

     

    Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    SMTG:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

     

    NAM:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) x  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k) ¨  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment Adviser, Parent Holding Company

     

     Page 5 of 9 
     

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    SMTG:    
         
      (a)   Amount beneficially owned: 2,315,294
           
      (b)   Percent of class: 8.56%
           
      (c)   Number of shares as to which such person has:
           
      (i)   Sole power to vote or to direct the vote: 0
           
      (ii)   Shared power to vote or to direct the vote: 2,315,294
           
      (iii)   Sole power to dispose or to direct the disposition of: 0
           
      (iv)  

    Shared power to dispose or to direct the disposition of: 2,315,294

           
    NAM:    
         
      (a)   Amount beneficially owned: 2,315,294
           
      (b)   Percent of class: 8.56%
           
      (c)   Number of shares as to which such person has:
           
      (i)   Sole power to vote or to direct the vote: 0
           
      (ii)   Shared power to vote or to direct the vote: 2,315,294
           
      (iii)   Sole power to dispose or to direct the disposition of: 0
           
      (iv)   Shared power to dispose or to direct the disposition of: 2,315,294

     

     Page 6 of 9 
     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    See Exhibit A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 9 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 5, 2024

     

      Sumitomo Mitsui Trust Group, Inc.
      (Company)
       
      /s/ Hideaki Takamiya
     

    (Signature)

     

    Hideaki Takamiya / Senior Manager of Risk Management Dept 

      (Name/Title)
       
      Nikko Asset Management Co.,Ltd 
      (Company)
       
      /s/ Atsushi Ohya
     

    (Signature)

     

    Atsushi Ohya / Head of Business Regulatory Compliance 

      (Name/Title)

     

     Page 8 of 9 
     

     

    Exhibit A

     

    Pursuant to the instructions in Item 6 and Item 7 of Schedule 13G, the securities being reported on by each of SMTG and NAM, as parent holding companies, are owned, or may be deemed to be beneficially owned, by their subsidiary Nikko Asset Management Americas, Inc., which is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    In addition, SMTH has changed the company name to SMTG as of October 1, 2024.

     

     

    Page 9 of 9

     

     

     

    Get the next $ARCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARCT

    DatePrice TargetRatingAnalyst
    1/28/2025$41.00Buy
    BTIG Research
    8/12/2024$70.00Outperform
    Leerink Partners
    12/13/2023$90.00Buy
    Canaccord Genuity
    7/24/2023$71.00Outperform
    William Blair
    5/11/2023$19.00 → $51.00Neutral → Buy
    H.C. Wainwright
    11/14/2022$35.00Overweight
    Wells Fargo
    11/10/2022$18.00Neutral → Underperform
    Robert W. Baird
    11/3/2022$22.00 → $35.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ARCT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Arcturus Therapeutics Holdings Inc.

      DEF 14A - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      4/25/25 5:15:29 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

      SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/25/25 6:18:10 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.

      SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/23/25 8:14:38 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/8/24 3:17:24 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arcturus Therapeutics Holdings Inc.

      SC 13G - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      11/5/24 6:07:26 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Arcturus Therapeutics Holdings Inc. (0001768224) (Subject)

      4/5/24 12:18:33 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Arcturus Therapeutics with a new price target

      BTIG Research initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $41.00

      1/28/25 8:51:42 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Arcturus Therapeutics with a new price target

      Leerink Partners initiated coverage of Arcturus Therapeutics with a rating of Outperform and set a new price target of $70.00

      8/12/24 7:16:41 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Arcturus Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $90.00

      12/13/23 8:02:48 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1 subtype contained in the vaccine. This designation recognizes the potential of ARCT-2304 as an innovative approach to address unmet medical needs for the prevention of disease caused by pandemic influ

      4/10/25 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

      Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat

      3/6/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Financials

    Live finance-specific insights

    See more

    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Foun

      4/22/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

      Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U.S. BLA filing anticipated 2025 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updat

      3/6/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 6, 2025. Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call Thursday, March 6, 2025 @4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURU

      2/24/25 4:01:00 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Kurata Lance

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:07:29 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Payne Joseph E

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:59 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer & COO Chivukula Pad

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      12/18/24 4:06:26 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

      Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. "Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate," said Joseph Payne, President & Chief Executive Officer of Arcturus. "We look forward to working with him as we enter a transformative yea

      2/4/25 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

      Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors. "Dr. Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and comm

      6/20/24 8:00:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Appoints John Markels, Ph.D. to its Board of Directors

      Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company's vaccine franchise Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Markels will provide strategic oversight to the C

      12/13/22 8:30:00 AM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care